|
|
Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma
Arthur Bobin
,
Maéva Kyheng
,
Stephanie Guidez
,
Cecile Gruchet-Merouze
,
Valentine Richez
et al.
Journal articles
hal-03476700v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Venetoclax-Targeted Therapy in t(11;14) AL Amyloidosis Patients after Frontline Daratumumab and Cybord: A Retrospective Analysis from the French Amyloidosis Network
Murielle Roussel
,
Michelle Pirotte
,
Ornella Rizzo
,
Kentin Queru
,
Thomas Chalopin
et al.
Conference papers
hal-04071489v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Salvage Therapy Post Pomalidomide-Based Regimen in Relapsed/Refractory Myeloma
Guillemette Fouquet
,
Lionel Karlin
,
Margaret Macro
,
Denis Caillot
,
Murielle Roussel
et al.
Blood, 2015, 126 (23), pp.1831
Journal articles
hal-01300804v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma
Guillemette Fouquet
,
Lionel Karlin
,
Margaret Macro
,
Denis Caillot
,
Murielle Roussel
et al.
Journal articles
hal-01728968v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03) / 57th Annual Meeting of the American-Society-of-Hematology - Orlando, FL
Xavier Leleu
,
Lionel Karlin
,
Brigitte Kolb
,
Mourad Tiab
,
Carla Araujo
et al.
Blood, 2015, 126 (23), pp.3028
Journal articles
hal-01290431v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma
Charlotte Fontan
,
Mourad Tiab
,
Pascal Godmer
,
Odile Luycx
,
Olivier Allangba
et al.
Journal articles
hal-01439375v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).
Arnaud Jaccard
,
Raymond L. Comenzo
,
Parameswaran Hari
,
Philip N. Hawkins
,
Murielle Roussel
et al.
Journal articles
hal-01064573v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Impact of Poor Tolerance and Discontinuation of the Dexamethasone during Treatment with Lenalidomide-Dexamethasone in Relapsed and Refractory Multiple Myeloma
Stephanie Guidez
,
Guillemette Fouquet
,
Helene Demarquette
,
Morgane Nudel
,
Eileen Boyle
et al.
Blood, 2015, 126 (23), pp.5379
Journal articles
hal-01290429v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.
Xavier Leleu
,
Lionel Karlin
,
Margaret Macro
,
Cyrille Hulin
,
Laurent Garderet
et al.
Journal articles
hal-01141134v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL
Norbert Schmitz
,
Lorenz Truemper
,
Krimo Bouabdallah
,
Marita Ziepert
,
Mathieu Leclerc
et al.
Journal articles
hal-03163608v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Clinical characteristics and outcome of 318 families with familial monoclonal gammopathy: A multicenter Intergroupe Francophone du Myélome study
Charles Dumontet
,
Delphine Demangel
,
Perrine Galia
,
Lionel Karlin
,
Laurent Roche
et al.
Journal articles
hal-03980698v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02
Xavier Leleu
,
Michel Attal
,
Bertrand Arnulf
,
Philippe Moreau
,
Catherine Traulle
et al.
Journal articles
hal-01064417v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|